{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:20:08Z","timestamp":1790018408021,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.7759\/cureus.106266","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:48:42Z","timestamp":1775044122000},"source":"Crossref","is-referenced-by-count":1,"title":["Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease"],"prefix":"10.7759","author":[{"given":"Mukosolu F","family":"Obi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shardil","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamsy","family":"Ezechukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"17","author":"Brown E","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021, 17:262-76. 10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001007","article-title":"Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes","volume":"8","author":"McCoy RG","year":"2020","unstructured":"McCoy RG, Lipska KJ, Van Houten HK, Shah ND. Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. BMJ Open Diabetes Res Care. 2020, 8:10.1136\/bmjdrc-2019-001007","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13010016","article-title":"Anti-inflammation and anti-oxidation: the key to unlocking the cardiovascular potential of SGLT2 Inhibitors and GLP1 receptor agonists","volume":"13","author":"Myasoedova VA","year":"2023","unstructured":"Myasoedova VA, Bozzi M, Valerio V, et al.. Anti-inflammation and anti-oxidation: the key to unlocking the cardiovascular potential of SGLT2 Inhibitors and GLP1 receptor agonists. Antioxidants (Basel). 2023, 13:10.3390\/antiox13010016","journal-title":"Antioxidants (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dci20-0053","article-title":"Social determinants of health and diabetes: a scientific review","volume":"44","author":"Hill-Briggs F","year":"2020","unstructured":"Hill-Briggs F, Adler NE, Berkowitz SA, et al.. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2020, 44:258-79. 10.2337\/dci20-0053","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.02.003","article-title":"Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries","volume":"236","author":"Batchelor WB","year":"2021","unstructured":"Batchelor WB, Damluji AA, Yong C, et al.. Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries. Am Heart J. 2021, 236:37-48. 10.1016\/j.ahj.2021.02.003","journal-title":"Am Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.29011\/2577-2228.100460","article-title":"Health and racial disparities in diabetes mellitus prevalence, management, policies, and outcomes in the United States","volume":"8","author":"Yedjou CG","year":"2024","unstructured":"Yedjou CG, Sims JN, Njiki S, Chitoh AM, Joseph M, Cherkos AS, Tchounwou PB. Health and racial disparities in diabetes mellitus prevalence, management, policies, and outcomes in the United States. J Community Med Public Health. 2024, 8:10.29011\/2577-2228.100460","journal-title":"J Community Med Public Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng Z","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024, 9:234. 10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon V","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017, 60:215-25. 10.1007\/s00125-016-4157-3","journal-title":"Diabetologia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacasi.2023.11.010","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart\u00a0failure: role of regional\/ethnic differences: focus on Asia","volume":"4","author":"Crisci G","year":"2024","unstructured":"Crisci G, Salzano A. Sodium-glucose cotransporter-2 inhibitors in heart\u00a0failure: role of regional\/ethnic differences: focus on Asia. JACC Asia. 2024, 4:119-22. 10.1016\/j.jacasi.2023.11.010","journal-title":"JACC Asia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/01410768231198442","article-title":"Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"117","author":"Kunutsor SK","year":"2024","unstructured":"Kunutsor SK, Khunti K, Seidu S. Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. J R Soc Med. 2024, 117:267-83. 10.1177\/01410768231198442","journal-title":"J R Soc Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100784","article-title":"Challenges in achieving racial and ethnic health equity in type 2 diabetes: access to newer medications","volume":"34","author":"Piya MK","year":"2024","unstructured":"Piya MK, Hocking S. Challenges in achieving racial and ethnic health equity in type 2 diabetes: access to newer medications. Lancet Reg Health Am. 2024, 34:100784. 10.1016\/j.lana.2024.100784","journal-title":"Lancet Reg Health Am"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07428-1","article-title":"Racial and ethnic inequities in diabetes pharmacotherapy: Black and Hispanic patients are less likely to receive SGLT2is and GLP1as","volume":"37","author":"Cai C","year":"2022","unstructured":"Cai C, Woolhandler S, McCormick D, Himmelstein DU, Himmelstein J, Schrier E, Dickman SL. Racial and ethnic inequities in diabetes pharmacotherapy: Black and Hispanic patients are less likely to receive SGLT2is and GLP1as. J Gen Intern Med. 2022, 37:3501-3. 10.1007\/s11606-022-07428-1","journal-title":"J Gen Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052821","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: racial differences and a potential for reducing disparities","volume":"143","author":"Morris AA","year":"2021","unstructured":"Morris AA, Testani JM, Butler J. Sodium-glucose cotransporter-2 inhibitors in heart failure: racial differences and a potential for reducing disparities. Circulation. 2021, 143:2329-31. 10.1161\/CIRCULATIONAHA.120.052821","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05554-9","article-title":"Racial differences in all-cause mortality and future complications among people with diabetes: a systematic review and meta-analysis of data from more than 2.4 million individuals","volume":"64","author":"Ezzatvar Y","year":"2021","unstructured":"Ezzatvar Y, Ram\u00edrez-V\u00e9lez R, Izquierdo M, Garc\u00eda-Hermoso A. Racial differences in all-cause mortality and future complications among people with diabetes: a systematic review and meta-analysis of data from more than 2.4 million individuals. Diabetologia. 2021, 64:2389-401. 10.1007\/s00125-021-05554-9","journal-title":"Diabetologia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.26099\/vabp-0g69","article-title":"Disparities in the Use of New Diabetes Medications: Widening Treatment Inequality by Race and Insurance Coverage","author":"Ding D","year":"2022","unstructured":"Ding D, Glied SA. Disparities in the Use of New Diabetes Medications: Widening Treatment Inequality by Race and Insurance Coverage. Commonwealth Fund, New York City; 2022. 10.26099\/vabp-0g69"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110233","article-title":"Disparities in adoption of new diabetic therapies with cardiovascular benefits","volume":"196","author":"Vasti EC","year":"2023","unstructured":"Vasti EC, Basina M, Calma J, Maron DJ, Rodriguez F, Sandhu AT. Disparities in adoption of new diabetic therapies with cardiovascular benefits. Diabetes Res Clin Pract. 2023, 196:110233. 10.1016\/j.diabres.2022.110233","journal-title":"Diabetes Res Clin Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100759","article-title":"Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"34","author":"Rodriguez LA","year":"2024","unstructured":"Rodriguez LA, Finertie H, Neugebauer RS, et al.. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Lancet Reg Health Am. 2024, 34:100759. 10.1016\/j.lana.2024.100759","journal-title":"Lancet Reg Health Am"},{"key":"ref19","article-title":"SGLT2 inhibitor therapy is prescribed to Black and Asian patients at lower rates than White patients","author":"Nye J","year":"2024","unstructured":"Nye J. SGLT2 inhibitor therapy is prescribed to Black and Asian patients at lower rates than White patients. Cardiol Advisor. 2024, June 5.","journal-title":"Cardiol Advisor"},{"key":"ref20","article-title":"Black, Asian, female patients less likely to receive SGLT2 inhibitor prescription","author":"Schaffer R","year":"2021","unstructured":"Schaffer R. Black, Asian, female patients less likely to receive SGLT2 inhibitor prescription. Endocrine Today. 2021, April 16.","journal-title":"Endocrine Today"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae655","article-title":"Sex-specific cardiovascular risk factors and treatment in females with T2DM and CVD: developments and knowledge gaps","volume":"109","author":"LeBlanc ES","year":"2024","unstructured":"LeBlanc ES, Brooks N, Davies M, Chatterjee R. Sex-specific cardiovascular risk factors and treatment in females with T2DM and CVD: developments and knowledge gaps. J Clin Endocrinol Metab. 2024, 109:e2167-77. 10.1210\/clinem\/dgae655","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01354-2","article-title":"Real-world effectiveness of once-weekly glucagon-like peptide-1 receptor agonists (OW GLP-1RAs) in comparison with dipeptidyl peptidase-4 inhibitors (DPP-4is) for glycemic control and weight outcomes in type 2 diabetes mellitus (RELATE)","volume":"44","author":"Tan X","year":"2024","unstructured":"Tan X, Divino V, Amamoo J, et al.. Real-world effectiveness of once-weekly glucagon-like peptide-1 receptor agonists (OW GLP-1RAs) in comparison with dipeptidyl peptidase-4 inhibitors (DPP-4is) for glycemic control and weight outcomes in type 2 diabetes mellitus (RELATE). Clin Drug Investig. 2024, 44:271-84. 10.1007\/s40261-024-01354-2","journal-title":"Clin Drug Investig"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomized controlled trials.","volume":"13","author":"Badve SV","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, et al.. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomized controlled trials. . Lancet Diabetes Endocrinol. 2025, 13:15-28. 10.1016\/s2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.12147","article-title":"Diabetes care barriers, use, and health outcomes in younger adults with type 1 and type 2 diabetes","volume":"6","author":"Pihoker C","year":"2023","unstructured":"Pihoker C, Braffett BH, Songer TJ, et al.. Diabetes care barriers, use, and health outcomes in younger adults with type 1 and type 2 diabetes. JAMA Netw Open. 2023, 6:e2312147. 10.1001\/jamanetworkopen.2023.12147","journal-title":"JAMA Netw Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly LA","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, et al.. Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021, 4:e216139. 10.1001\/jamanetworkopen.2021.6139","journal-title":"JAMA Netw Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0905","article-title":"Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity","volume":"6","author":"Hwang JH","year":"2025","unstructured":"Hwang JH, Laiteerapong N, Huang ES, Mozaffarian D, Fendrick AM, Kim DD. Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity. JAMA Health Forum. 2025, 6:e250905. 10.1001\/jamahealthforum.2025.0905","journal-title":"JAMA Health Forum"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf301","article-title":"Overcoming disparities in using SGLT2 inhibitors for cardiorenal protection in persons with and without type 2 diabetes","volume":"110","author":"Jack GA","year":"2025","unstructured":"Jack GA, Avenatti E, Kashyap SR, Sadhu AR. Overcoming disparities in using SGLT2 inhibitors for cardiorenal protection in persons with and without type 2 diabetes. J Clin Endocrinol Metab. 2025, 110:e2852-63. 10.1210\/clinem\/dgaf301","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.100966","article-title":"Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system","volume":"22","author":"Bolden DM","year":"2025","unstructured":"Bolden DM, Richardson V, Salahuddin T, et al.. Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system. Am J Prev Cardiol. 2025, 22:100966. 10.1016\/j.ajpc.2025.100966","journal-title":"Am J Prev Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06321-2","article-title":"Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013-2019","volume":"68","author":"Wang E","year":"2025","unstructured":"Wang E, Patorno E, Khosrow-Khavar F, Crystal S, Dave CV. Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013-2019. Diabetologia. 2025, 68:94-104. 10.1007\/s00125-024-06321-2","journal-title":"Diabetologia"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.202492bypcyh","article-title":"Racial disparities in SGLT2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP-1 RA) use in the US Military Health System (MHS): TH-PO1013","volume":"35","author":"Oliver J. D.","year":"2024","unstructured":"Oliver J. D., Nee R., Marneweck H., et al.. Racial disparities in SGLT2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP-1 RA) use in the US Military Health System (MHS): TH-PO1013. J Am Soc Nephrol. 2024, 35:10.1681. 10.1681\/ASN.202492bypcyh","journal-title":"J Am Soc Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133079","article-title":"Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: a systematic review and meta-analysis","volume":"426","author":"Kani R","year":"2025","unstructured":"Kani R, Miyamoto Y, Saito T, et al.. Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: a systematic review and meta-analysis. Int J Cardiol. 2025, 426:133079. 10.1016\/j.ijcard.2025.133079","journal-title":"Int J Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00129-8","article-title":"Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward","volume":"11","author":"Hassan S","year":"2023","unstructured":"Hassan S, Gujral UP, Quarells RC, et al.. Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward. Lancet Diabetes Endocrinol. 2023, 11:509-24. 10.1016\/S2213-8587(23)00129-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0383","article-title":"Deficits and disparities in early uptake of glucagon-like peptide 1 receptor agonists and SGLT2i among Medicare-insured adults following a new diagnosis of cardiovascular disease or heart failure","volume":"46","author":"Cromer SJ","year":"2023","unstructured":"Cromer SJ, Lauffenburger JC, Levin R, Patorno E. Deficits and disparities in early uptake of glucagon-like peptide 1 receptor agonists and SGLT2i among Medicare-insured adults following a new diagnosis of cardiovascular disease or heart failure. Diabetes Care. 2023, 46:65-74. 10.2337\/dc22-0383","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455877-unequal-access-to-evidence-based-cardiometabolic-therapies-racial-disparities-in-sglt2-inhibitor-and-glp-1-receptor-agonist-use-among-patients-with-type-2-diabetes-and-cardiovascular-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:48:43Z","timestamp":1775044123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455877-unequal-access-to-evidence-based-cardiometabolic-therapies-racial-disparities-in-sglt2-inhibitor-and-glp-1-receptor-agonist-use-among-patients-with-type-2-diabetes-and-cardiovascular-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.106266","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}